Pfizer posted adjusted earnings of 66 cents per share, beating the 57 cents forecast by analysts, News.Az reports, citing foreign media.
Quarterly revenue came in at $17.6 billion, above expectations of $16.8 billion.
RECOMMENDED STORIES
Investor sentiment, however, was weighed down by guidance that fell short of consensus estimates. Pfizer reaffirmed its 2026 outlook issued in December, projecting revenue between $59.5 billion and $62.5 billion and adjusted earnings of $2.80 to $3.00 per share. Analysts surveyed by FactSet had been expecting revenue of $61.9 billion and earnings of $3.12 per share. The company also said its guidance does not include any stock buybacks.
Pfizer shares were down about 0.6% in premarket trading, while futures tied to the S&P 500 rose slightly.
Ahead of its earnings release, Pfizer announced positive topline results from a study evaluating monthly maintenance dosing of its injectable GLP-1 receptor agonist in overweight adults without type 2 diabetes. The company also said it plans to launch 20 key pivotal studies in 2026.
Pfizer remains widely known for its COVID-19 vaccine, Comirnaty, which was co-developed with BioNTech and became the first vaccine to receive emergency use authorization in 2020. However, COVID-related sales have become a less significant contributor to Pfizer’s revenue in recent years.
The company’s other major products include its Prevnar family of vaccines and Nurtec, a migraine treatment that surpassed $1 billion in sales last year. Pfizer acquired Nurtec through its purchase of Biohaven Pharmaceuticals in 2022.
